Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > May 7, 2020
Daily News
May 7, 2020
- Kyowa Kirin’s Q1 Sales Tick Up as North America Revenue Counters Japan Dip
May 7, 2020
- Gilead Japan Expected to Offer Remdesivir for Free for Now
May 7, 2020
- Establish Development Regime to Always Be Prepared for New Infectious Disease, Global Health Confab Urges amid COVID-19
May 7, 2020
- Japan to Test Ivermectin for COVID-19: Prime Minister
May 7, 2020
- Japan Eyes May Approval for Avigan with Investigator-Led Study Data
May 7, 2020
- Fujifilm to Carry Out Process Development, Manufacturing of COVID-19 Treatment for Anti-COVID-19 Initiative
May 7, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…